2024 | Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study | Subbiah, Vivek; Hu, Mimi I; Mansfield, Aaron S; Taylor, Matthew H; Schuler, Martin; Zhu, Viola W; Hadoux, Julien; Curigliano, Giuseppe; Wirth, Lori; Gainor, Justin F; Alonso, Guzman; Adkins, Douglas; Godbert, Yann; Ahn, Myung-Ju; Cassier, Philippe A; Cho, Byoung Chul; CHIA-CHI LIN ; Zalutskaya, Alena; Barata, Teresa; Trask, Peter; Scalori, Astrid; Bordogna, Walter; Heinzmann, Sebastian; Brose, Marcia S | Thyroid : official journal of the American Thyroid Association | 1 | | |
2023 | Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial | Hurvitz, Sara A; Hegg, Roberto; Chung, Wei-Pang; Im, Seock-Ah; Jacot, William; Ganju, Vinod; Chiu, Joanne Wing Yan; Xu, Binghe; Hamilton, Erika; Madhusudan, Srinivasan; Iwata, Hiroji; Altintas, Sevilay; Henning, Jan-Willem; Curigliano, Giuseppe; Perez-Garcia, José Manuel; Kim, Sung-Bae; Petry, Vanessa; CHIUN-SHENG HUANG ; et al., | Lancet (London, England) | 142 | 77 | |